Home/Filings/4/0001415889-25-001242
4//SEC Filing

Fordyce Marshall 4

Accession 0001415889-25-001242

CIK 0001831828other

Filed

Jan 9, 7:00 PM ET

Accepted

Jan 10, 4:06 PM ET

Size

18.4 KB

Accession

0001415889-25-001242

Insider Transaction Report

Form 4
Period: 2025-01-08
Fordyce Marshall
DirectorPRESIDENT AND CEO
Transactions
  • Exercise/Conversion

    Class A Common Stock

    2025-01-08$2.90/sh+9,975$28,896153,578 total
  • Sale

    Class A Common Stock

    2025-01-08$41.53/sh9,975$414,297143,603 total
  • Exercise/Conversion

    Class A Common Stock

    2025-01-08$2.90/sh+5,650$16,367149,253 total
  • Sale

    Class A Common Stock

    2025-01-08$42.03/sh5,650$237,489143,603 total
  • Exercise/Conversion

    Class A Common Stock

    2025-01-08$2.90/sh+1,875$5,432145,478 total
  • Sale

    Class A Common Stock

    2025-01-08$42.00/sh1,875$78,750143,603 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-01-081,875609,051 total
    Exercise: $2.90Exp: 2030-12-15Class A Common Stock (1,875 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-01-0815,625610,926 total
    Exercise: $2.90Exp: 2030-12-15Class A Common Stock (15,625 underlying)
Holdings
  • Class A Common Stock

    (indirect: By GRAT)
    222,030
Footnotes (4)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
  • [F2]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.89 to $41.85, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F3]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.87 to $42.19, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F4]1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.

Issuer

Vera Therapeutics, Inc.

CIK 0001831828

Entity typeother

Related Parties

1
  • filerCIK 0001859453

Filing Metadata

Form type
4
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 4:06 PM ET
Size
18.4 KB